Nuvilex (NASDAQ:PMCB – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, Zacks reports.
Nuvilex Stock Up 1.9%
PMCB stock traded up $0.02 on Thursday, reaching $0.84. 529,527 shares of the company’s stock were exchanged, compared to its average volume of 889,598. Nuvilex has a twelve month low of $0.63 and a twelve month high of $1.90. The stock has a fifty day moving average of $0.91 and a 200-day moving average of $0.98. The firm has a market cap of $5.71 million, a PE ratio of -1.56 and a beta of 0.06.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (d)” rating on shares of Nuvilex in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.
About Nuvilex
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
Recommended Stories
- Five stocks we like better than Nuvilex
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500
- Energy and Oil Stocks Explained
- Forget the Chips: 4 Industrial Plays for the AI Rebound
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- MongoDB Could Hit Record Highs—But You’ll Need to Move Fast
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
